Novonesis (Novozymes) B

NZM2

Company Profile

  • Business description

    Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs more than 11,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.

  • Contact

    Krogshoejvej 36
    Bagsvaerd2880
    DNK

    T: +45 44460000

    https://www.novonesis.com

  • Sector

    Basic Materials

    Stock type

    Cyclical

  • Industry

    Specialty Chemicals

    Fiscal Year End

    31 December 2026

    Employees

    11,641

Stocks News & Analysis

stocks

Older cohorts the budget losers, not necessarily the ASX listed insurers

Proposed legislation removes health insurance rebates.
stocks

Turnaround progressing for ASX share

Margins have rebased by shares are undervalued.
stocks

Investors overlooking ASX share’s potential

International expansion is a distraction from valuable local business.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,735.4083.10-0.94%
CAC 407,987.490.000.00%
DAX 4024,307.92357.351.49%
Dow JONES (US)49,546.0419.870.04%
FTSE 10010,323.75128.381.26%
HKSE25,675.18287.55-1.11%
NASDAQ25,959.39265.75-1.01%
Nikkei 22560,815.95593.34-0.97%
NZX 50 Index12,762.92202.09-1.56%
S&P 5007,372.7735.73-0.48%
S&P/ASX 2008,505.3072.60-0.85%
SSE Composite Index4,131.533.86-0.09%

Market Movers